SYNACTHEN - Medsafe
Lack of diagnostic accuracy: Post administration total plasma cortisol levels during the Synacthen test might be misleading in some special clinical situations due to altered cortisol binding globulin
Download SYNACTHEN - Medsafe
Information
Domain:
Source:
Link to this page:
Documents from same domain
ADVANTAN Presentation Uses - Medsafe
www.medsafe.govt.nzADVANTAN® Data Sheet Page 1 of 9 ADVANTAN® Methylprednisolone aceponate 0.1% ointment/cream . Presentation 1 g cream or ointment contains 1 mg (0.1%) methylprednisolone aceponate.
LOXALATE 1. Product Name - Medsafe Home Page
www.medsafe.govt.nzPage 5of 21 at risk, such as the elderly, or patients with cirrhosis, or if used in combination with other medications which may cause hyponatraemia.
DATA SHEET 1 CLEXANE AND CLEXANE FORTE ... - …
www.medsafe.govt.nzNew Zealand Data Sheet June 2017 . clexane-clexane-forte-ccdsv13-dsv18-16jun17 Page 2 . 100 mg injection enoxaparin sodium 100mg (equivalent to …
SEPTANEST Articaine hydrochloride 4% with …
www.medsafe.govt.nzSEPTANEST Articaine hydrochloride 4% with adrenaline 1:100,000 Injection for local and regional dental anaesthesia DESCRIPTION SEPTANEST is a sterile aqueous solution that contains articaine hydrochloride 4% (40 mg/mL) with adrenaline acid tartrate in a 1:100,000 strength.
BOOSTRIX - Medsafe Home Page
www.medsafe.govt.nz1 BOOSTRIX®. Combined diphtheria, tetanus, acellular pertussis (dTpa) vaccine . CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET? This leaflet answers some of the common questions about BOOSTRIX vaccine.
NEW ZEALAND DATA SHEET - Medsafe
www.medsafe.govt.nzNEW ZEALAND DATA SHEET Cymevene ® DS 170831 2 of 26 Caution: Cymevene must only be administered by IV infusion over 1 hour, preferably via a
Edition Draft - Medsafe
www.medsafe.govt.nzPart 4, Ed Draft Page 2 of 9 Section 1: Good Manufacturing Practice Documentation 1.1. When is GMP Documentation Required? Medsafe requires evidence of Good Manufacturing Practice (GMP) compliance for
Data Sheet 1 PRODUCT NAME 2 QUALITATIVE AND …
www.medsafe.govt.nzNew Zealand Data Sheet 31 July 2017 Lantus – insulin glargine lantus-ccdsv19-dsv11-31jul17 Page 1 Data Sheet 1 PRODUCT NAME Lantus 100 IU/mL solution for injection in 10 …
NEW ZEALAND DATA SHEET MESTINON® - Medsafe
www.medsafe.govt.nzNEW ZEALAND DATA SHEET MESTINON® MESTINON Page 4 of 8 As the severity of myasthenia gravis often fluctuates considerably, particular care is required to
DATA SHEET PREDNISONE - Medsafe
www.medsafe.govt.nz• Epilepsy and/or seizure disorder • Peptic ulceration • Previous steroid myopathy • Tuberculosis • Patients with myasthenia gravis receiving anticholinesterase therapy since
Related documents
Endocrinology Handbook Endocrine Unit Imperial College ...
imperialendo.co.uk7 ANTERIOR PITUITARY ANTERIOR PITUITARY FUNCTION INSULIN TOLERANCE TEST (ITT) INDICATION Assessment of ACTH and cortisol reserve. Assessment of growth hormone reserve in children with definite growth retardation and a subnormal
LORSTAT 1. Product Name 2. Qualitative and Quantitative ...
www.medsafe.govt.nzPage 2of 21 Lorstat is indicated as an adjunct to diet for the treatment of patients with elevated serum triglyceride levels (hypertriglyceridaemia), and for the treatment of patients with
CORTISOL WEANING COMPILATION - National Adrenal …
www.nadf.usCORTISOL WEANING COMPILATION Taken from various NADF News® Issues. (edited 12/11/17) From NADF News®, VOL. XXI, No. 1 • 2006 Q & A By Paul Margulies, M.D., FACE, FACP
PRODUCT MONOGRAPH - Valeo Pharma
www.valeopharma.com- 3 - functional reserve of the adrenal cortex, a 5-hour test can be performed using SYNACTHEN DEPOT. Plasma-cortisol should be estimated before and 4-6 hours after an i.m. injection of 1 mg
ASRA/ESRA/INS/AAPM/WIP/NANS guidelines for …
www.worldinstituteofpain.org4 and redirection of the leads.1,3 Further, trial and permanent implantation processes may be sequential (partial implantation) or separated depending on patient, continental, payor or physician preferences.